Stanford researchers use CRISPR to edit sickle cell mutations, possibly laying the groundwork for a clinical trial, Reuters reports.
In Science this week: approach to uncover recent changes in allele frequencies, and more.
Utah's Dana Carroll, UC Berkeley's Jacob Corn, and their colleagues replaced the sickle cell disease mutation with the wild-type gene via HDR.
Researchers describe using a CRISPR approach to edit the sickle cell gene in vitro, the Los Angeles Times reports.
In PNAS this week: work toward a CRISPR/Cas9-based approach to treat beta-thalassemia or sickle cell disease, bacteriophages uncovered in human stool, and more.
In Nature this week: Exome Aggregation Consortium analysis of some 60,000 exomes, and more.
Scientists introduced an indel to a promoter region to mimic a benign, naturally-occurring mutation that activated fetal hemoglobin production.
Protective genetic mutations are providing a blueprint for companies wanting to treat sickle cell, Scientific American reports.
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
By editing a promoter of an enhancer of the mutated hemoglobin responsible for sickle cell disease, the researchers may have found a way to treat it.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.